In a collaborative project leadXpro (LXP) and Cumulus identified small molecules for therapies in oncology and inflammation. Cumulus has licensed the small molecule compounds and associated IP created during this collaboration and will continue the programme to lead optimisation and beyond through its Swiss-based portfolio company. LXP will receive a share in revenues from future commercialisation of the project.
